Samsung Biologics Co Ltd
207940 · KO · Healthcare / Biotechnology
$1,398,000+2000.00 (+0.14%)
Close Sep 18, 2026 · end-of-day
Market Stats
Previous Close$1,396,000
Open$1,407,000
Day Range$1,386,000 – $1,414,000
52-Week Range$1,228,000 – $1,987,000
Volume32.55K
Market Cap$66.15T
P/E (TTM)0.00
Forward P/E34.84
Dividend Yield0.00%
Beta0.21
50-Day Avg$1,000,000
200-Day Avg$1,000,000
Price History
Open in new tabLoading price history…
About
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Company Details
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John Chongbo Rim
- Employees
- 5.33K
- Headquarters
- 300, Songdo bio-daero, Incheon, South Korea, Korea
- Website
- https://samsungbiologics.com
Leadership
- Mr. John Chongbo RimCEO, President & Chairman of Board · b. 1961
- Dr. Kun Lo Ph.D.Executive VP, Head of EPCV Center & Director · b. 1963
- Mr. Seung ho RyuEVP, CFO, Head of Business Support Center & Director · b. 1968
- Mr. Kevin SharpEVP, Head of Sales & Operations Department
- Mr. Kyuho LeeExecutive VP, Head of People Center, & Chief Human Resource Officer
- Mr. James J. ChoiExecutive VP, Head of CDO Development Center & Head of Sales Center · b. 1967
- Mr. Heekyun LimVP & Head of Business Consulting Team · b. 1975
- Sojeong LeeVP & Head of Regulatory Affairs
- Ms. Heejeong KimVP & Head of Drug Substance Department
- Mr. Sangmyung LeeVP & Head of CDO Development
Financials
Income Statement
| Line item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.56T | $3.50T | $3.69T | $3.00T | $1.57T | $1.16T | $701.59B | $535.81B | $464.63B | $294.62B | $91.28B | $105.15B |
| Cost of Revenue | $2.04T | $1.79T | $1.89T | $1.53T | $841.56B | $748.70B | $509.58B | $390.65B | $332.83B | $268.09B | $116.81B | $125.85B |
| Gross Profit | $2.52T | $1.71T | $1.80T | $1.47T | $726.45B | $416.08B | $192.01B | $145.16B | $131.80B | $26.53B | $-25.54B | $-20.70B |
| Operating Income | $2.07T | $1.32T | $1.11T | $983.63B | $537.31B | $292.79B | $91.74B | $55.68B | $65.98B | $-30.42B | $-203.64B | $-119.54B |
| EBITDA | $2.78T | $2.02T | $1.69T | $1.38T | $737.78B | $425.77B | $313.94B | $410.26B | $-40.38B | - | - | - |
| Net Income | $1.78T | $1.08T | $857.69B | $798.06B | $393.59B | $240.97B | $202.90B | $224.11B | $-96.97B | $-176.82B | $1.92T | $-95.91B |
| R&D | $37.18B | $36.71B | $81.59B | $45.88B | $954.22M | $5.11B | - | - | - | - | - | $186.74M |
| Interest Expense | $29.17B | $34.12B | $81.60B | $64.06B | $14.71B | $16.09B | $25.61B | $15.84B | $0 | $0 | $0 | $0 |
Balance Sheet
| Line item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.06T | $17.34T | $16.05T | $16.58T | $7.97T | $6.42T | $5.91T | $5.98T | $7.18T | $7.53T | $5.96T | $1.36T |
| Total Liabilities | $3.61T | $6.43T | $6.22T | $7.60T | $2.98T | $1.83T | $1.56T | $1.82T | $3.21T | $3.45T | $3.19T | $724.97B |
| Total Equity | $7.45T | $10.90T | $9.83T | $8.98T | $4.99T | $4.60T | $4.35T | $4.16T | $3.98T | $4.08T | $2.77T | $598.14B |
| Cash | $148.85B | $391.22B | $367.94B | $890.82B | $47.41B | $28.85B | $125.10B | $17.62B | $358.09B | $230.34B | $34.51B | $96.29B |
| Net Debt | $769.87B | $948.54B | $1.26T | $1.21T | $1.23T | $733.51B | $512.72B | $855.07B | $187.82B | - | - | - |
Cash Flow
| Line item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.25T | $1.66T | $1.67T | $953.05B | $454.60B | $202.09B | $10.15B | $-33.02B | $149.82B | $-62.66B | $-265.51B | $-108.30B |
| Investing Cash Flow | - | - | - | $-3.11T | $-933.49B | $-418.69B | $339.64B | $-631.39B | $265.19B | $-1.37T | $-429.48B | $-581.83B |
| Financing Cash Flow | - | - | - | $3.00T | $496.62B | $122.56B | $-239.81B | $323.94B | $-287.18B | $1.63T | $633.22B | $682.02B |
| Capital Expenditure | $1.48T | $1.38T | $1.11T | $956.84B | $406.25B | $139.66B | $192.84B | $278.65B | $494.12B | $168.17B | $240.33B | $365.93B |
| Free Cash Flow | $772.73B | $281.73B | $560.90B | $-56.18B | $33.44B | $53.52B | $-171.04B | $-316.88B | $-354.99B | - | - | - |
Earnings
| Report Date | Oct 27, 2026 | Aug 14, 2026 | May 15, 2026 | Feb 25, 2026 | Nov 14, 2025 | Aug 14, 2025 | May 15, 2025 | Feb 25, 2025 | Nov 14, 2024 | Aug 14, 2024 | May 16, 2024 | Feb 28, 2024 | Nov 14, 2023 | Aug 14, 2023 | Apr 24, 2023 | Mar 9, 2023 | Nov 14, 2022 | Aug 16, 2022 | May 16, 2022 | Mar 2, 2022 | Nov 15, 2021 | Aug 17, 2021 | Apr 28, 2021 | Mar 30, 2021 | Nov 16, 2020 | Jul 21, 2020 | Apr 20, 2020 | Jan 22, 2020 | Oct 23, 2019 | Jul 23, 2019 | Apr 24, 2019 | Jan 31, 2019 | Oct 23, 2018 | Jul 23, 2018 | Apr 24, 2018 | Jan 31, 2018 | Oct 25, 2017 | Jul 24, 2017 | May 15, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Estimate | $9718.00 | $9873.54 | $9544.89 | $11382.97 | $10335.52 | $7073.89 | $5919.31 | $5062.18 | $5186.37 | $5187.03 | $4060.43 | $4733.11 | $4833.92 | $3629.50 | $2128.63 | $4337.94 | $3622.99 | $2445.92 | $2798.86 | $2256.37 | $3064.76 | $2008.46 | $1174.43 | $6554.67 | $4098.27 | $947.20 | $839.40 | $866.18 | $311.95 | $-118.52 | $-130.38 | $4849.61 | $212.50 | $206.00 | $99.00 | $37.33 | $-154.00 | $-175.50 | - |
| EPS Actual | - | $9314.00 | $10148.00 | $8723.00 | $8071.00 | $7008.09 | $8113.58 | $6945.05 | $5713.48 | $6869.71 | $3874.59 | $6279.30 | $5190.72 | $3992.98 | $1992.00 | $6863.56 | $2798.32 | $2215.59 | $3279.56 | $1199.00 | $3119.66 | $3008.96 | $911.21 | $2349.35 | $930.21 | $776.80 | $547.52 | $3184.00 | $667.00 | $-203.00 | $-581.00 | $4795.00 | $-455.00 | $-145.00 | $-865.00 | $-153.00 | $-479.00 | $-334.00 | $-494.61 |
| Surprise | - | -5.67% | 6.32% | -23.37% | -21.91% | -0.93% | 37.07% | 37.19% | 10.16% | 32.44% | -4.58% | 32.67% | 7.38% | 10.01% | -6.42% | 58.22% | -22.76% | -9.42% | 17.17% | -46.86% | 1.79% | 49.81% | -22.41% | -64.16% | -77.30% | -17.99% | -34.77% | 267.59% | 113.82% | -71.28% | -345.62% | -1.13% | -314.12% | -170.39% | -973.74% | -509.86% | -211.04% | -90.31% | - |
| Timing | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | After-hours | Pre-market | Pre-market | Pre-market | After-hours | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | Pre-market | After-hours |
Key Statistics & Ratios
- Market Cap
- $66.15T
- Enterprise Value
- $62.19T
- Trailing P/E
- 0.00
- Forward P/E
- 34.84
- PEG Ratio
- 1.69
- Price / Sales
- 12.92
- Price / Book
- 7.55
- Revenue (TTM)
- $5.12T
- Gross Profit (TTM)
- $2.78T
- EBITDA
- $2.83T
- Profit Margin
- 38.75%
- Operating Margin
- 44.40%
- Return on Equity
- 18.53%
- Return on Assets
- 9.57%
- Shares Outstanding
- 46.29M
- Shares Float
- 11.81M
- Beta
- 0.21
- Dividend Yield
- 0.00%
- Dividend Rate
- $0
- Payout Ratio
- 0.00%
Stock Splits
- Oct 30, 20250.6504:1